Stock Events

Stock Events

MoonLake Immunotherapeutics 

M$305.3
142
+M$0+0% Thursday 15:44

Statistics

Day High
305.3
Day Low
305.3
52W High
305.3
52W Low
305.3
Volume
120
Avg. Volume
120
Mkt Cap
19.45B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-20.45
-16.51
-12.56
-8.62
Expected EPS
-16.915612319999997
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-4.99BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MLTXN.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the immunology and inflammation treatment space, directly challenging MoonLake's focus on novel therapeutics for autoimmune diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a strong portfolio in immunology, including treatments for conditions that MoonLake targets, making it a direct competitor in the autoimmune disease market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen operates in the biotechnology industry focusing on human therapeutics, including treatments for inflammatory diseases, competing with MoonLake's offerings.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the discovery, development, and commercialization of medicines in areas similar to MoonLake, including inflammatory and immune-mediated diseases.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a range of biopharmaceutical products that target immune system disorders, directly competing with MoonLake's therapeutic areas.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on patented medicines for a range of diseases, including autoimmune and inflammation, making it a competitor in MoonLake's market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for autoimmune diseases, competing with MoonLake's immunotherapeutic approaches.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse portfolio in biopharmaceuticals, including drugs for inflammatory and autoimmune diseases, positioning it as a competitor to MoonLake.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is engaged in the development of pharmaceutical products, including for immune-mediated diseases, competing with MoonLake's focus areas.
Rogers
ROG
Mkt Cap1.57B
Roche Holding AG, with its strong focus on biotechnology and medications for autoimmune diseases, competes in the same space as MoonLake, particularly in the development of innovative therapeutics.

About

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Show more...
CEO
ISIN
KY61559X1045

Listings

MX
MX
MLTXN.MX
XNAS
US
MLTX
BOATS
BOATS
MLTX.BOATS

0 Comments

Share your thoughts

FAQ

What is MoonLake Immunotherapeutics stock price today?▼
The current price of MLTXN.MX is M$305.3 MXN — it has increased by +0% in the past 24 hours. Watch MoonLake Immunotherapeutics stock price performance more closely on the chart.
What is MoonLake Immunotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MoonLake Immunotherapeutics stocks are traded under the ticker MLTXN.MX.
What is MoonLake Immunotherapeutics market cap?▼
Today MoonLake Immunotherapeutics has the market capitalization of 19.45B
When is the next MoonLake Immunotherapeutics earnings date?▼
MoonLake Immunotherapeutics is going to release the next earnings report on February 26, 2026.
What were MoonLake Immunotherapeutics earnings last quarter?▼
MLTXN.MX earnings for the last quarter are -20.45 MXN per share, whereas the estimation was -16.34 MXN resulting in a -25.17% surprise. The estimated earnings for the next quarter are N/A MXN per share.
What is MoonLake Immunotherapeutics revenue for the last year?▼
MoonLake Immunotherapeutics revenue for the last year amounts to 0 MXN.
What is MoonLake Immunotherapeutics net income for the last year?▼
MLTXN.MX net income for the last year is -4.99B MXN.
When did MoonLake Immunotherapeutics complete a stock split?▼
MoonLake Immunotherapeutics has not had any recent stock splits.